In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas
about
BH3 domains other than Bim and Bid can directly activate Bax/BakCurrent challenges and novel treatment strategies in double hit lymphomasMYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical managementTargeting Mcl-1 for the therapy of cancerSynergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanomaThe use of therapeutic peptides to target and to kill cancer cells.Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also BimApoptotic cell signaling in cancer progression and therapyCoexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivityIntracellular delivery system for antibody-Peptide drug conjugatesPharmacological blockade of Bcl-2, Bcl-x(L) and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice.Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cellsThe BCL-2 protein family, BH3-mimetics and cancer therapy.Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.Oncogenes in cell survival and cell death.Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response.Prophylactic treatment with the BH3 mimetic ABT-737 impedes Myc-driven lymphomagenesis in miceMitochondrial permeability transition pore as a selective target for anti-cancer therapyRNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model.Perforin-mediated suppression of B-cell lymphomaMYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphomaMcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.New developments in the pathology of malignant lymphoma: a review of the literature published from August to December 2008.Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterpartsTargeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation.Using body temperature, food and water consumption as biomarkers of disease progression in mice with Eμ-myc lymphoma.Deciphering the rules of programmed cell death to improve therapy of cancer and other diseasesMYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.
P2860
Q24305138-061D5C43-670B-4D2C-8E21-B9A6784C4E35Q26770385-B086F005-00D3-4272-B2DC-4598AE996494Q26785379-1E37AFCD-DE45-468D-B71D-0B50B3F096AAQ27011870-A58AA050-8446-45D3-8BE6-71B80A1C5C23Q28476828-54BBB456-8439-4FEB-9C0B-1C967E0C14EFQ30418414-57C7DE18-17FB-4ECE-B3DB-209801691BC5Q33398808-62F4C832-F2E0-4C9D-BD09-429D91BB570EQ33405436-4665BE4B-CA84-4B8A-AF95-F42DF387125CQ33438494-96E4B6D0-1E80-41EE-BBED-DCA6ECA4CEF6Q34369809-9549A0DE-F568-44CB-BC5D-E2E7A5700132Q34450473-8B2EFAAF-08D0-4FA7-AB7B-03D1847544D4Q35088734-CB70E436-F5D9-4F07-81FC-E62CA45C9768Q35128216-270E52D0-9A05-4FDD-A816-40430B18ECDDQ35212727-D4E049A3-501A-4D1E-BB45-FE237B616BDBQ35493953-44D2061F-F0C8-43F3-8CA6-B72F98676377Q35594851-56C91B07-C092-4395-B50C-80CCC305E6E2Q35678266-89E0E86B-BC0B-4C8B-B103-75EB328066C0Q36057611-2C0E7191-CA09-4B75-8341-BF8FDB66F2C1Q36067778-BFB7EFC0-2A2F-4E19-A3E3-B11B52390991Q36267666-C01DC0F5-0518-4D7B-9442-EA8028900190Q36418000-2F8ECBFD-5F1B-4A0F-B835-EA3FA8B9BE62Q36471376-B1E49C49-45DC-440B-9BE1-95B9AD4A1A14Q36473581-D0595493-91F6-4920-B702-EA2C19A90C6DQ36668047-A766D7B0-B417-41D0-AF28-8C928E88089CQ36797266-633E0760-B17C-4929-A6D8-6E8E09C8D446Q37115217-3D2849E6-C09A-42C3-B506-246162FEDBAEQ37142412-84C96AEB-35FB-4C0E-B636-D093D85B7B1AQ37163339-00A059F8-D0F9-4221-9DEF-B13ABA85770BQ37235693-5AA41E12-3B11-4F12-A154-C357F334BD7AQ37269044-E6B129B7-1FB6-4FFF-AF7E-B3AE03DD37DAQ37330840-10DD5CE0-372B-4099-8751-8EF9D7D82D51Q37347239-746481DE-A288-4BDA-8F1E-3A61A64C3918Q37351043-10C27469-AB1A-49C6-B3FB-F9FC70B91A82Q37425601-879BA134-2B2C-4B9A-81B8-6680B0A645E9Q37488736-2FFA9723-B217-40D7-BC8E-5393EE7CFEF4Q37521403-6864ED47-3A09-4774-8093-273EDE2FFEC6Q37594415-227F00B8-E6C3-462F-9FB9-DA1AA3EE1DC3Q37921609-055E0C29-C43B-459D-94A7-2E9DABF13DCDQ38233772-B84009C7-7D50-46AF-B4C6-DAE3D06CCEFCQ38640917-9DE6C682-B39C-4E4B-B542-325BC567A4C8
P2860
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas
@en
type
label
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas
@en
prefLabel
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas
@en
P2093
P2860
P50
P356
P1476
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas
@en
P2093
Andrew H Wei
Cassandra J Vandenberg
Clare L Scott
P2860
P304
17961-17966
P356
10.1073/PNAS.0809957105
P407
P577
2008-11-11T00:00:00Z